Skip to main content Skip to secondary navigation
Main content start
IMA Leadership

Chaitan Khosla

Marc and Jennifer Lipschultz Director of the Stanford Innovative Medicines Accelerator (IMA)
Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and Professor of Chemistry and, by courtesy, of Biochemistry

Prof. Chaitan Khosla brings his expertise in human health research and his experience in translating academic research to industry to his role as Director of the IMA. Research in Prof. Khosla's laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health. Specifically, he is interested in enzymatic assembly lines that synthesize polyketide antibiotics and in the pathogenesis of celiac disease with the goal of discovering therapies for this widespread but overlooked disease. Prof Khosla has co-founded three companies based on this research, including Kosan Biosciences, founded in 1995 and acquired by Bristol-Myers Squibb in 2008; Alvine Pharmaceutics, founded in 2006 and acquired by ImmunogenX in 2016; and Sitari Pharmaceuticals, founded in 2013 and acquired by GlaxoSmithKline in 2019

Return to IMA Leadership page